A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

被引：44
|
作者：
Badros, Ashraf Z. [1 ]
Kocoglu, Mehmet H. [1 ]
Ma, Ning [1 ]
Rapoport, Aaron P. [1 ]
Lederer, Emily [1 ]
Philip, Sunita [1 ]
Lesho, Patricia [1 ]
Dell, Cameron [1 ]
Hardy, Nancy M. [1 ]
Yared, Jean [1 ]
Goloubeva, Olga [1 ]
Singh, Zeba [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.506.506
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] POMALIDOMIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): EXPERIENCE CENTER
    Cuesta Garcia, A.
    HAEMATOLOGICA, 2015, 100 : 104 - 104
  • [32] A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Hilger, James D.
    Klein, Leonard M.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2012, 120 (21)
  • [33] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
  • [34] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
    Gasparetto, Cristina
    Green, Michael
    Srinivasan, Anandgopal
    Kang, Yubin
    Rizzieri, David A.
    Decastro, Carlos
    Diehl, Louis F.
    Beaven, Anne
    Li, Zighuo
    Rao, Arati V.
    Garrett, Anderson
    Tuchman, Sascha
    Long, Gwynn D.
    BLOOD, 2015, 126 (23)
  • [36] Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
    Chng, Wee-Joo
    Li, Xinhua
    Lin, Cindy
    Kim, Jin Seok
    Handa, Hiroshi
    Durie, Brian G. M.
    BLOOD, 2020, 136
  • [37] PANOBINOSTATPK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Mu, S.
    Tajima, T.
    Corrado, C.
    Sunami, K.
    Suzuki, K.
    Hino, M.
    Kuroda, Y.
    Shibayama, H.
    Lin, R.
    Waldron, E.
    Binlich, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S49 - S49
  • [38] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Ray
    Wang, Jim
    Masterson, Tara
    Nottage, Kerri
    Schecter, Jordan
    Chiu, Christopher
    Khokhar, Nushmia
    Ahmadi, Tahamtan
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15
  • [39] Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1 b Study (NCT01999335)
    Shah, Jatin
    Niesvizky, Ruben
    Stadtmauer, Edward
    Rifkin, Robert M.
    Berenson, James
    Berdeja, Jesus G.
    Sharman, Jeff P.
    Lyons, Roger
    Klippel, Zandra
    Wong, Hansen
    Chang, Yu-Lin
    Usmani, Saad
    BLOOD, 2015, 126 (23)
  • [40] Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study
    Baz, Rachid
    Martin, Thomas G.
    Alsina, Melissa
    Shain, Kenneth H.
    Cho, Hearn J.
    Wolf, Jeffrey L.
    Mahindra, Anuj
    Chari, Ajai
    Sullivan, Daniel M.
    Nardelli, Lisa A.
    Lau, Kenneth
    Zhao, Xiuhua
    Lin, Hui-Yi
    Jagannath, Sundar
    BLOOD, 2014, 124 (21)
12345